Do vitamin D supplements prevent cancer? Two large randomised trials say no
VITAL, with 25,871 adults, and D-Health, with 21,315, both tested vitamin D against placebo. Neither cut cancer incidence or cancer death — and one saw a signal pointing the wrong way.
Vitamin D supplements do not appear to prevent cancer. Two of the largest randomised, placebo-controlled trials ever run on the question — one in the United States, one in Australia — tested daily or monthly vitamin D against a dummy pill in tens of thousands of adults, and neither found a reduction in cancer incidence or cancer death. This is the highest-quality evidence available, and it points clearly away from the popular idea that topping up vitamin D lowers cancer risk.
Why randomised trials matter here
Observational studies have long linked low blood levels of vitamin D to higher rates of several cancers. But blood vitamin D is entangled with everything from sunlight exposure and outdoor activity to body weight and general health, so an association tells you little about whether swallowing a supplement changes anything. The only way to isolate the supplement's effect is to randomly assign people to take it or not, and then wait. Two trials did exactly that.
VITAL: 25,871 adults, no reduction in cancer
The VITAL trial, published in the New England Journal of Medicine, randomised 25,871 US adults — men aged 50 or older and women aged 55 or older, including 5,106 Black participants — to vitamin D3 at 2000 IU per day or placebo, in a design that also tested omega-3 fish oil [s1].
Over a median follow-up of 5.3 years, invasive cancer of any type was diagnosed in 1,617 participants — 793 in the vitamin D group and 824 in the placebo group [s1]. The hazard ratio was 0.96, with a 95% confidence interval of 0.88 to 1.06 (P=0.47) — a result statistically indistinguishable from no effect [s1]. Death from cancer, a secondary endpoint, gave a hazard ratio of 0.83 (95% confidence interval 0.67 to 1.02), a suggestion of possible benefit that did not reach statistical significance [s1]. For individual sites the numbers were flat: breast cancer 1.02, prostate 0.88, colorectal 1.09, all with intervals crossing 1 [s1]. The trial's own conclusion was blunt: vitamin D did not lower the incidence of invasive cancer [s1].
D-Health: 21,315 adults, and a signal pointing the wrong way
The Australian D-Health trial used a different regimen — a large monthly dose of 60,000 IU — in 21,315 people aged 60 or older, randomised to vitamin D3 or placebo for five years [s2]. Blood testing confirmed the supplement worked biochemically: mean serum 25-hydroxy-vitamin D reached 115 nmol/L in the vitamin D group versus 77 in the placebo group [s2].
Its primary endpoint was all-cause mortality, and there was no benefit: hazard ratio 1.04 (95% confidence interval 0.93 to 1.18) [s2]. For cancer mortality specifically, the hazard ratio was 1.15 (95% confidence interval 0.96 to 1.39, P=0.13) — not significant, but numerically above 1 [s2]. In an exploratory analysis that excluded the first two years of follow-up, participants on vitamin D had a numerically higher hazard of cancer death (hazard ratio 1.24, 95% confidence interval 1.01 to 1.54, P=0.05) [s2]. The investigators were careful about what this does and does not mean: it is an exploratory finding, not a primary result, but it is enough that they invoked the precautionary principle, suggesting this high monthly dose "might not be appropriate in people who are vitamin D-replete" [s2].
Reading the two trials together
The consistent message is that supplementing largely vitamin-D-sufficient older adults does not prevent cancer [s1][s2]. VITAL found no effect on incidence and a non-significant hint of lower cancer death; D-Health found no effect on mortality and, if anything, a hint in the harmful direction for cancer death [s1][s2]. Those two mortality signals do not cancel to a clean "no effect" so much as bracket it — the honest reading is that any true effect is small and its direction is not established.
Several caveats bound the conclusion. Both trials enrolled populations that were mostly vitamin-D-sufficient at baseline, so they cannot say whether correcting genuine deficiency changes cancer risk [s1][s2]. Both followed participants for roughly five to six years, and cancer takes longer than that to develop, so a delayed benefit cannot be fully excluded [s1][s2]. And neither studied children or younger adults.
What the trials do settle is the everyday version of the question. For an older adult taking vitamin D in the hope of preventing cancer, the best available randomised evidence does not support that hope. This article is informational and is not medical advice; decisions about supplementation, especially where deficiency or bone health is involved, are clinical ones.
Sources
- [s1] Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease — New England Journal of Medicine, 3 January 2019. https://doi.org/10.1056/NEJMoa1809944
- [s2] The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality — The Lancet Diabetes & Endocrinology, published online 10 January 2022. https://doi.org/10.1016/S2213-8587(21)00345-4
Sources
- Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease — New England Journal of Medicine , January 3, 2019
- The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality — The Lancet Diabetes & Endocrinology , January 10, 2022
More on
High-dose vitamin D didn't slow metastatic colorectal cancer in a phase 3 trial
SOLARIS, a publicly funded phase 3 trial, tested vitamin D3 added to chemotherapy after a promising phase 2 signal. Progression-free survival was 11.8 versus 10.3 months — not a significant difference.
Can you get all your vitamins from food? Mostly yes, with a few documented exceptions
A varied diet covers most of the 13 essential vitamins. The evidence-based exceptions are specific: vitamin D is hard to get from food, older adults and vegans need B12, and folic acid is advised before pregnancy.
Signs of vitamin D deficiency, and why most adults are told to skip the routine test
Real deficiency shows as bone pain, muscle weakness or, in children, rickets. But US surveys suggest most people meet their needs, and both a 2011 and a 2024 review advise against routine testing in healthy adults.
Omega-3 slowed biological-age clocks in a trial, by a few months over three years
The DO-HEALTH sub-study is the first randomised evidence that a supplement can nudge DNA-methylation ageing clocks. The effect was tiny, and the parent trial found no benefit on health outcomes that matter.